Abstract
Lung transplant recipients (LTRs) mismatched for CMV (D+R-) are at highest risk for active CMV infection and have increased 1-and 5-year mortality. We have previously shown the acquisition of functional CMV-specific CD8+ T cells during primary infection with persistence into chronic infection. However, we observed relapsing viremia within the first 6 months following primary infection in 30% of our D+R- cohort following discontinuation of antiviral therapy. Therefore, we compared CMV-specific CD8+ T cell responses in those LTRs with relapsing viremia compared to those who demonstrated immune control.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
